MediciNova (NASDAQ:MNOV) announced the completion of the last patient’s final visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS).
aTyr Pharma (NASDAQ:ATYR) announced FDA alignment on the planned Phase 3 study protocol for efzofitimod in patients with pulmonary sarcoidosis on September 24, 2026.
Kyverna Therapeutics (NASDAQ:KYTX) reported updated clinical data for its investigational CAR-T therapy miv-cel (mivocabtagene autoleucel) in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).
HUTCHMED (NASDAQ:HCM) will present results from two Phase III studies evaluating savolitinib combined with osimertinib in lung cancer patients at ESMO Congress 2026.
Afya (NASDAQ:AFYA) entered a binding merger agreement with Yduqs Participações S.A. to combine the two Brazilian higher education companies.
AtlasClear Holdings (NYSE:ATCH) reported fiscal 2026 revenue of $20.1 million for the year ended June 30, 2026, representing an 85% increase from the prior year.
Novartis (NYSE:NVS) won a lawsuit in Manhattan federal court after a judge dismissed claims that the company improperly used an Entresto patent listing to delay generic competition.
Bio-Techne (NASDAQ:TECH) shareholders approved the proposed acquisition by Merck KGaA, Darmstadt, Germany, at a special meeting held on September 23, 2026.
Immunovant (NASDAQ:IMVT) reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, with the study failing to meet its primary endpoint.
Oruka Therapeutics (NASDAQ:ORKA) reported positive Week 28 results from the Phase 2a EVERLAST-A trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.
AC Immune (NASDAQ:ACIU) reported that all primary endpoints were met at week 100 in Part 1 of its Phase 2 VacSYn trial evaluating ACI-7104 in early Parkinson’s disease.
Roivant (NASDAQ:ROIV) reported topline results from Immunovant’s proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, with the study failing to meet its primary endpoint.
